NCT04766515 Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
| NCT ID | NCT04766515 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2020-09-01 |
| Primary Completion | 2023-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2020-09-01 with a primary completion date of 2023-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.
Eligibility Criteria
Inclusion Criteria: * Age at least 18 years. * Pathologically confirmed diagnosis of a solid tumor cancer. * Patients receiving treatment with immune checkpoint inhibitors. * Ability to understand and willingness to provide the informed consent. Exclusion Criteria: * Age \< 18 years. * Patients with hematological malignancies or solid benign tumors. * Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.
Contact & Investigator
Zhengfei Zhu, MD
PRINCIPAL INVESTIGATOR
Fudan University
Frequently Asked Questions
Who can join the NCT04766515 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04766515 currently recruiting?
Yes, NCT04766515 is actively recruiting participants. Contact the research team at fuscczzf@163.com for enrollment information.
Where is the NCT04766515 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04766515 clinical trial?
NCT04766515 is sponsored by Fudan University. The principal investigator is Zhengfei Zhu, MD at Fudan University. The trial plans to enroll 6,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.